At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
VIR-2218 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a
In Brief
A Phase 2 clinical trial evaluating VIR-2218 and pegylated interferon-alfa 2a for Chronic Hepatitis B. Completed, enrolled 84 participants across 22 sites in 6 countries.
Detailed Summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesAustralia, Hong Kong, Malaysia, New Zealand, South Korea, Thailand
CollaboratorsAlnylam Pharmaceuticals
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionMar 2024
TodayJul 2026
First PostedJun 2, 2020
Enrollment StartJul 3, 2020
Primary CompletionMar 25, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.1 years ago
Interventions
VIR-2218drug
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2adrug
pegylated interferon-alfa 2a given by subcutaneous injection